CARDINAL (TERN-701) = TERN-701 in Chronic Myeloid Leukemia [USA]
Study title
Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in participants with chronic myeloid leukemia
Scientific title
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
Type of study
Trial after therapy failure or intolerance
Phase
Current status
Recruitment to start in December 2023
Other trial ID
TERN701-1012; ClinicalTrials.gov NCT06163430
What is the purpose of the study
The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a novel highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase – chronic myeloid leukemia (CP-CML).
What will happen during the study
The study has two parts: Part 1 of the trial (Dose Escalation) will evaluate dose escalation cohorts of TERN-701 administered once daily.
Part 2 (Dose Expansion) consists of randomized, parallel dose expansion cohorts of TERN-701 that will further evaluate the efficacy and safety of at least 2 recommended dose levels for expansion selected from Part 1.
In both Part 1 and Part 2, participants will receive continuous daily dosing of TERN-701 divided into 28-day cycles.
Key inclusion criteria
This study includes male or female patients who:
- are aged 18 years or older at the time of signing the informed consent
- have an Eastern Co-Operative Group (ECOG) status of 0, 1 or 2
- have stablished cytopathologically confirmed diagnosis of BCR-ABL1 positive chronic myeloid leukemia in chronic phase (CML-CP) with or without T315l mutation
- have received treatment with active site targeting TKIs and have treatment failure, suboptimal response, or treatment intolerance
- are intolerant of asciminib, and do not have resistant/relapsing disease
- have adequate end organ function.
Further criteria apply. Please discuss these with your doctor or study staff.
Key exclusion criteria
This study does not include patients who:
- have CML in accelerated or blast phase
- have been treated with systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of TERN-701
- have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline).
Further criteria apply. Please discuss these with your doctor or study staff.
Estimated primary completion date
Where can I find additional information
You can find a study description in the US registry ClinicalTrials.gov. This is a database provided by the U. S. National Institutes of Health.
Study sponsor
Terns, Inc.
Scientific lead / contact
Principal investigator
Study centers / principal investigators
United States
Texas
The University of Texas MD Anderson Cancer Center